Company intelligence / Profile preview

Revotar Biopharmaceuticals

Hennigsdorf, Brandenburg, Germanyorpha.net ↗

Ownership: Private
Development stage: Phase 2

Overview

Revotar’s lead candidate, bimosiamose—a pan-selectin antagonist—has completed several Phase I and IIa clinical trials in asthma, COPD, and psoriasis. Results have shown a good safety and efficacy profile in nearly 200 patients and volunteers. The company has also reported positive top-line results from a Phase II trial with inhaled bimosiamose for respiratory diseases such as COPD. Additional preclinical programs are focused on other anti-inflammatory targets.

Therapeutic areas: PulmonologyDermatology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

bimosiamose

Partnerships

Texas Biotechnology Corporation/TBCoUndisclosed US pharma partner

Beyond the preview

Go deeper on Revotar Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revotar Biopharmaceuticals.

Explore the full profile